NMDP BioTherapies
NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development
January 30, 2024 09:00 ET | NMDP
NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president.
Hemato Oncology Testing Market Anticipated to Surge Amid Technological Innovations and Increased Cancer Prevalence
January 22, 2024 21:23 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
January 17, 2024 16:01 ET | Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
Transparency Market Research
Anticancer Drugs Market Size & Share to Surpass USD 303.1 billion by 2031 | Analysis by Transparency Market Research, Inc.
December 14, 2023 04:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global anticancer drugs market was projected to attain US$ 140.2 billion in 2022. It is...
Kura Oncology Logo
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
December 08, 2023 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Bancroft Creative Group
Gift of Life Marrow Registry Drives Awareness, Celebrates Lives Saved at NHL Hockey Fights Cancer Night
December 01, 2023 10:22 ET | Gift of Life Marrow Registry
Gift of Life Marrow Registry teamed up with the Florida Panthers and Nashville Predators for NHL’s Hockey Fights Cancer initiative.
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023 16:01 ET | Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
November 07, 2023 16:05 ET | Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Vor Bio to Participate in Upcoming Investor Conferences
November 03, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
November 02, 2023 09:01 ET | Vor Biopharma
Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and...